Cargando…
Newly formulated GROWJECT(®) is bioequivalent to the prior GROWJECT(®) formulation and causes less injection-associated pain
Daily treatment with subcutaneous injections of recombinant human GH can be physically and emotionally stressful for children and their caregivers owing to the pain caused by injection. In this study, 52 healthy male subjects were randomized to investigate the bioequivalence and compare the safety a...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Japanese Society for Pediatric Endocrinology
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783130/ https://www.ncbi.nlm.nih.gov/pubmed/33446950 http://dx.doi.org/10.1297/cpe.30.35 |